MedPath

Olutasidenib Plus Azacitidine Shows Promise in IDH1-Mutated Relapsed/Refractory AML

• A pooled analysis from a Phase I/II trial demonstrates the efficacy of olutasidenib combined with azacitidine in patients with IDH1-mutated relapsed/refractory acute myeloid leukemia.

• The FDA-approved mutant IDH1 inhibitor olutasidenib was evaluated in combination therapy across multiple trial cohorts involving 67 patients with R/R AML.

• The study, published in the Journal of Hematology & Oncology, assessed key endpoints including complete response rates, transfusion independence, and overall survival.

The treatment landscape for relapsed/refractory acute myeloid leukemia (R/R AML) continues to evolve with promising results from a combination therapy approach. A comprehensive pooled analysis has revealed important findings for patients with IDH1-mutated R/R AML, offering new hope in this challenging disease setting.

Combination Therapy Assessment

The multicenter, open-label Phase I/II trial (NCT02719574) investigated the therapeutic potential of combining olutasidenib, an FDA-approved mutant IDH1 inhibitor, with azacitidine. The study encompassed multiple cohorts, analyzing data from 67 patients with IDH1-mutated R/R AML.

Study Design and Endpoints

Researchers structured the trial to evaluate both efficacy and safety parameters. The investigation prioritized several key measurements:
  • Primary endpoint: Complete response/Complete response with partial hematologic recovery (CR/CRh) rate
  • Secondary endpoints:
    • Overall response rate (ORR)
    • 56-day transfusion independence rate
    • Time to response
    • Duration of response (DoR)
    • Overall survival (OS)

Clinical Implementation Context

This research builds upon olutasidenib's existing FDA approval for IDH1-mutated R/R AML, exploring its potential in combination therapy. The addition of azacitidine to the treatment protocol represents an important investigation into optimizing therapeutic outcomes for this specific patient population.
The findings from this pooled analysis, published by Cortes et al. in the Journal of Hematology & Oncology, contribute valuable insights to the growing body of evidence supporting targeted approaches in AML treatment. The 5-year follow-up data provides crucial information about the long-term implications of this therapeutic strategy.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Oryzon's Iadademstat Enters Phase I Trial for Myelodysplastic Syndrome

Oryzon Genomics has announced the dosing of the first patient in a Phase I trial of iadademstat for myelodysplastic syndrome (MDS).
The trial, led by the Medical College of Wisconsin, will assess the safety, tolerability, and optimal dose of iadademstat with azacitidine.

IO-202 Plus Azacitidine Shows Promise in Treating CMML

IO-202 combined with azacitidine achieved a 50% complete remission rate and a 66.7% overall response rate in CMML patients naive to hypomethylating agents.
Notably, patients with high LILRB4 expression showed an 83.3% complete remission rate and a 100% overall response rate with the combination therapy.

Decitabine Plus CHAG Regimen Shows Promise in Relapsed/Refractory AML

A study shows that combining decitabine with the CHAG priming regimen yields a high complete remission rate (74.2%) in relapsed/refractory AML patients.
The overall response rate was 82.2%, with manageable side effects and no treatment-related deaths, suggesting a potential new treatment strategy.

Ipilimumab and Nivolumab Show Promise in Higher-Risk Myelodysplastic Syndromes

A Phase II trial evaluated ipilimumab and nivolumab, alone or in combination, for higher-risk myelodysplastic syndromes (MDS) patients who failed hypomethylating agents.
The combination of ipilimumab and nivolumab demonstrated the most promising overall response rate (ORR) and complete remission (CR) rate compared to single-agent therapies.

Revuforj (Revumenib) Shows Promising Results in Acute Leukemia Trials

Syndax Pharmaceuticals presented data from multiple trials of Revuforj (revumenib) at the ASH Annual Meeting, showcasing its efficacy in acute leukemias.
The SAVE trial showed an 82% overall response rate (ORR) and 48% complete remission rate (CR/CRh) when revumenib was combined with venetoclax and decitabine/cedazuridine in R/R AML.

Maze Therapeutics' MZE829 Shows Promise in Phase 1 Trial for APOL1 Kidney Disease

Maze Therapeutics announced positive Phase 1 results for MZE829, an oral APOL1 inhibitor, in healthy volunteers, showing it was well-tolerated with dose-proportional pharmacokinetics.
The trial supports once-daily dosing of MZE829 and its potential co-administration with standard-of-care medications for APOL1 kidney disease (AKD).

ASC22 and Chidamide Combination Shows Promise in Reducing HIV Reservoir Size

A Phase II clinical trial evaluated the combination of ASC22, an anti-PD-L1 antibody, and chidamide, a histone deacetylase inhibitor, in HIV-infected adults on ART.
The study demonstrated a reduction in total and integrated HIV DNA in PBMCs, suggesting a decrease in the HIV reservoir size after 12 weeks of treatment.

Rigel Pharmaceuticals Initiates Phase Ib/II Trial of REZLIDHIA Combination Therapy for mIDH1 AML

Rigel Pharmaceuticals has enrolled the first patient in a Phase Ib/II clinical trial evaluating REZLIDHIA (olutasidenib) in combination with decitabine and venetoclax for acute myeloid leukemia (AML).
The trial, sponsored by MD Anderson Cancer Center, aims to determine the safety, tolerability, and complete remission rate of the triplet therapy in patients with mutated isocitrate dehydrogenase-1 (mIDH1) AML.

FDA Approves Olutasidenib for Relapsed or Refractory AML with IDH1 Mutation

The FDA has granted approval to olutasidenib for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adult patients with a susceptible IDH1 mutation.
Approval was based on the Study 2102-HEM-101 trial, which showed a 35% complete remission (CR) plus CR with partial hematologic recovery (CRh) rate in patients treated with olutasidenib.

FDA Approves Ivosidenib Plus Azacitidine for IDH1-Mutated Acute Myeloid Leukemia

The FDA has approved ivosidenib in combination with azacitidine for previously untreated IDH1-mutated acute myeloid leukemia (AML).
The approval was based on the phase 3 AGILE trial, which demonstrated a statistically significant improvement in event-free survival (EFS) and overall survival (OS).

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy